Live Oak Private Wealth LLC Reduces Stock Position in Pfizer Inc. $PFE

Live Oak Private Wealth LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 92.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,627 shares of the biopharmaceutical company’s stock after selling 216,868 shares during the period. Live Oak Private Wealth LLC’s holdings in Pfizer were worth $449,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in PFE. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. WPG Advisers LLC bought a new position in Pfizer in the first quarter valued at $35,000. Magnetar Financial LLC purchased a new stake in Pfizer during the first quarter valued at about $1,823,000. Finally, Vident Advisory LLC boosted its holdings in shares of Pfizer by 761.7% in the 1st quarter. Vident Advisory LLC now owns 80,414 shares of the biopharmaceutical company’s stock worth $2,038,000 after purchasing an additional 71,082 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Stock Performance

Pfizer stock opened at $25.10 on Monday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The firm has a market cap of $142.68 billion, a P/E ratio of 14.59 and a beta of 0.46. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average of $25.16 and a 200-day moving average of $24.89.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.